Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
1999-09-23
2003-09-09
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C424S472000
Reexamination Certificate
active
06616932
ABSTRACT:
This invention relates to a liquid pharmaceutical preparation for oral delivery and to the preparation and use thereof. This invention further relates to liquid pharmaceutical preparations for oral delivery to children.
In many cases, it is desirable and/or necessary to deliver a pharmaceutical in liquid form. In general, in using such liquid pharmaceutical preparations, the pharmacist initially prepares a suspension of the pharmaceutically active material in a liquid carrier, and the suspension is placed into an appropriate container. At the time of use, the person using the preparation dispenses the liquid from the container into a spoon or dropper, which “measures” the amount of the liquid suspension for oral delivery of the suspension in the proper dosage. For example, in the case of antibiotics for oral delivery as a liquid, the antibiotic is prepared as a dry mix. When called upon to constitute and dispense such product, the pharmacist generally loosens the powder at the bottom of the container by lightly tapping it against the hard surface. However, if this is not done correctly, drug will remain as a cake at the bottom of the container, which will cause a sub-potent dose of drug to be administered to the patient. Once the drug is loosened in the container, the pharmacist proceeds to add the label designated amount to purified water. It is important that the pharmacist add the exact amount of purified water to the powder if the proper drug concentration per unit dose is to be achieved. Typically, purified water is needed to constitute current commercial dry pharmaceutical powders for oral suspension because of stability issues with tap water. In addition liquid suspension of a pharmaceutical may not be stable. This instability may occur over the typical 7-14 day shelf life of current constituted suspensions.
The thus prepared suspension contains a plurality of unit dosages, and, therefore, when being used, the person who is to take the pharmaceutical dispenses a specified amount of the liquid suspension from the container. In general, the container specifies that the unit dosage form that is to be used is a convenient measure such as 5 milliliters or one teaspoonful. However, teaspoons typically vary in volume, and to the extent that the volume of a teaspoon is inaccurate, the person dispensing or taking the liquid usually does not precisely dispense a teaspoonful.
As a result, there is a variation in the amount of drug that a patient receives that may result from the pharmacist preparing the liquid suspension or the patient dispensing an incorrect amount of the liquid suspension.
In accordance with an aspect of the present invention, there is provided a pharmaceutical composition, as well as a process for preparing a pharmaceutical composition for oral delivery in a liquid carrier that permits the formulation and dispensing of more accurate dosages of a pharmaceutically active agent or material for oral delivery in a liquid carrier.
In accordance with an embodiment of the invention, there is provided a solid unit dosage form, which at the time of use is added to a pharmaceutically acceptable liquid, such as water wherein the unit dosage form is comprised of a substrate and a particulate pharmaceutically active material deposited on such substrate with the pharmaceutically active material being present on the substrate in a pharmaceutically effective amount. The substrate is one that disintegrates rapidly in the liquid to form a solution or suspension suitable for oral delivery in the liquid. In this manner, at the time of use, the solid unit dosage form, is added to a liquid, and the pharmaceutically active material can be orally delivered in a pharmaceutically effective dosage without measuring the quantity of liquid carrier at the time of use. Thus, the solid unit dosage form contains the required amount of pharmaceutically active material, and when it is added to liquid, the substrate disintegrates rapidly, and the particulate pharmaceutically active material is dissolved or suspended in the liquid. The liquid may include a syrup or other sweetener in order to improve the palatability of the liquid and pharmaceutically active material. The entire amount of liquid is then swallowed and since the solid dosage form contains the required amount of pharmaceutically active material, there is no need to measure the quantity of liquid in order to prepare the proper dosage. The pharmaceutically active material may be comprised of one or more pharmaceutically active agents.
In a preferred embodiment, the solid unit dosage form is one in which the pharmaceutically active agent(s) or material(s) is deposited on the substrate as a layer separate and distinct from the substrate. In a particularly preferred embodiment, the pharmaceutically active agent(s) or material(s) is deposited as a separate and distinct layer on the substrate without being blended with non-pharmaceutically active material. Thus, the pharmaceutically active agent(s) or material(s), in the solid unit dosage form, is not blended with other materials.
In another embodiment, a small quantity of one or more taste modifiers may be deposited on the substrate with pharmaceutically active agent.
The substrate is preferably soluble in a pharmaceutically acceptable liquid such as water and, more preferably, rapidly dissolves therein. As representative examples of substrates that may be used in the present invention, there may be mentioned: gelatin, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, polyethylene oxide, polyvinylpyrrolidone, sodium alginate, carboxymethylcellulose, and agar. It is to be understood, however, that the scope of the invention is not limited to such substrates.
Thus, in accordance with an aspect of the present invention, there is provided a pharmaceutical composition that is a solid unit dosage form that is comprised of a substrate rapidly soluble in a pharmaceutically acceptable liquid such as water and a particulate pharmaceutically active material deposited on the substrate as a separate and distinct layer, wherein the pharmaceutically active material is present in a desired unit dosage amount, whereby the unit dosage form can be added to liquid, at the time of use, for oral delivery of the pharmaceutically active material in a liquid carrier.
In accordance with another aspect, the pharmaceutical composition is one which is for administration to children patients; i.e., patients no older than twelve years, wherein the amount of pharmaceutically active material present in the solid unit dosage form is both a pharmaceutically effective unit dosage amount and an amount suitable for administration to children.
In accordance with another aspect, the pharmaceutical composition is one which is for administration to geriatric patients; i.e., patients older than seventy years, wherein the amount of pharmaceutically active material present in the solid unit dosage form is both a pharmaceutically effective unit dosage amount and an amount suitable for administration to geriatric patients.
The invention is particularly applicable to the delivery of antibiotic and/or anti-viral and/or anti-fungal and/or anti-infective agents; however, the scope of the invention is not limited thereto. In a particularly preferred embodiment, the invention is directed to delivery of an antibiotic to children, wherein the unit dosage form contains a pharmaceutically effective amount of the antibiotic that is suitable for administration to children.
In accordance with a preferred embodiment of the present invention, a solid unit dosage form, which is to be added to a pharmaceutically acceptable liquid, such as water, for oral delivery in accordance with the present invention is preferably prepared by a process wherein the active ingredient is directly deposited onto an appropriate substrate, preferably by electrostatic deposition. Thus, for example, the pharmaceutically active material is electrostatically deposited onto substrate, which preferably dissolves rapidly in a pharmaceutically acceptable li
Chrai Suggy S.
Murari Ramaswamy
Delsys Pharmaceutical Corporation
Lillie Raymond J.
Olstein Elliot M.
Ware Todd D
LandOfFree
Liquid pharmaceutical for oral delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liquid pharmaceutical for oral delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liquid pharmaceutical for oral delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3030240